At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
OPC-34712drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-dose, Open-label, Parallel-group, Matched Trial Evaluating the Pharmacokinetics of Oral OPC-34712 Tablets in Subjects With Normal Renal Function and Renally Impaired Subjects
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Feb 3, 2011·Updated Oct 29, 2015
In Brief
A Phase 1 clinical trial evaluating OPC-34712 for Schizophrenia and Psychiatric Disorders. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Psychiatric Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedFeb 2011
Primary CompletionDec 2011
Study CompletionJan 2012
TodayJul 2026
First PostedFeb 3, 2011
Enrollment StartJan 1, 2011
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.4 years ago
Interventions
OPC-34712drug
administered orally